Lundbeck Set For 'Transformative' Eptinezumab Launch
February 21 PDUFA Date For Migraine Drug
The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.
